Loading
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
Previous close
$4.85
−$0.035 · -0.72%
Regular session · ET · Market data may be delayed.
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
Day range
Current $4.85
52-week range
Current $4.85
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
31
Expensive
Sentiment
46
Mixed
Risk
56
Elevated Risk
Momentum
38
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
Day range
Current $4.85
52-week range
Current $4.85
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 800K USD | 3.5M USD | 9.16M USD | 15.62M USD | 30.99M USD |
| Cost of goods sold | 1.03M USD | 1.53M USD | 1.02M USD | 64.32M USD | 47.11M USD |
| Gross profit | −233K USD | 1.97M USD | 8.14M USD | −48.7M USD | −16.12M USD |
| Research and development | 28.53M USD | 32.11M USD | 59.65M USD | 64.32M USD | 47.11M USD |
| Selling, general, and administrative | 20.73M USD | 8.39M USD | 24.93M USD | 22.2M USD | 18.02M USD |
| Operating expenses | 48.22M USD | 38.97M USD | 83.56M USD | 22.2M USD | 18.02M USD |
| Interest income | 2.04M USD | 7.37M USD | 7.11M USD | 2.15M USD | 23K USD |
| Depreciation and amortization | 1.03M USD | 1.53M USD | 1.02M USD | 751K USD | 544K USD |
| Operating income | −48.45M USD | −37M USD | −75.42M USD | −70.9M USD | −34.14M USD |
| Net income | −45.35M USD | −36.57M USD | −68.17M USD | −68.77M USD | −34.12M USD |
Company facts updated Sep 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$1.33
72.58% downside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jul 28, 2025 | 1:12 | — | — |
Effective Jul 28, 2025
1:12
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
